Targeting cytokines to inflammation sites

Nature Biotechnology

Volumn 21, Issue 11, 2003, Pages 1314-1320

  Adams, Gill ^a   Vessillier, Sandrine ^a   Dreja, Hanna ^b   Chernajovsky, Yuti ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DNA; PROTEINS;

CELLULAR RECEPTORS;

DISEASES;

BETA INTERFERON; CELL RECEPTOR; HYBRID PROTEIN; LATENCY ASSOCIATED PEPTIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BIOENGINEERING; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISULFIDE BOND; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME DEGRADATION; GENETIC CODE; HALF LIFE TIME; HUMAN; IN VIVO STUDY; INFLAMMATION; INJECTION; LATENT PERIOD; NONHUMAN; PRIORITY JOURNAL; RAT; SYNOVIAL FLUID;

ANIMALS; CELLS, CULTURED; CHEMOKINES; DRUG DELIVERY SYSTEMS; ENDOPLASMIC RETICULUM; GENE PRODUCTS, VPU; GENE TARGETING; HUMANS; MICE; OSTEITIS; RECEPTORS, CHEMOKINE; RECOMBINANT FUSION PROTEINS;

ANIMALIA;

EID: 0242353920     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt888     Document Type: Article

References (53)

1. Waldmann, T.A. & Tagaya, Y. The multifaceted regulation of IL-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17, 19-49 (1999).
2. Taniguchi, T. Regulation of cytokine gene expression. Annu. Rev. Immunol. 6, 439-464 (1988).
3. Taipale, J. & Keski-Oja, J. Growth factors in the extracellular matrix. FASEB J. 11, 51-59 (1997).
4. Khalil, N. TGF-β: from latent to active. Microbes Infect. 1, 1255-1263 (1999).
5. Aulitzky, W., Schuler, M., Peschel, C. & Huber, C. Interleukins: clinical pharmacology and therapeutic use. Drugs 48, 667-677 (1994).
6. Gutterman, J. Cytokine therapeutics: lessons from IFN α. Proc. Natl. Acad. Sci. USA 91, 1198-1205 (1994).
7. Golab, J. & Zagozdon, R. Antitumor effects of IL-12 in pre-clinical and early clinical studies. Int. J. Mol. Med. 3, 537-544 (1999).
8. Atkins, M. et al. High dose recombinant IL-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
9. Margolin, K.A. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27, 194-203 (2000).
10. Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D. & Reisfeld, R.A. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80, 277-292 (1998).
11. Han, B., Hall, F.L. & Nimni, M.E. Refolding of a recombinant collagen-targeted TGF β 2 fusion protein expressed in E. coli. Protein Expr. Purif. 11, 169-178 (1997).
12. Gordon, E.M. et al. Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a TGF β1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. Hum. Gene Ther. 8, 1385-1394 (1997).
13. Sanderson, N. et al. Hepatic expression of mature TGF-β1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 92, 2572-2576 (1995).
14. Brunner, A. et al. Site-directed mutagenesis of glycosylation sites in the transforming growth factor-β1 (TGF β 1) and TGF-β 2 (414) precursors and of cysteine residues within mature TGF β 1: effects on secretion and bioactivity. Mol. Endocrinol. 6, 1691-1700 (1992).
15. Brunner, A., Marquardt, H., Malacko, A., Lioubin, M. & Purchio, A. Site-directed mutagenesis of cysteine residues in the pro region of the TGF β 1 precursor, J. Biol. Chem. 264, 13660-13664 (1989).
16. Munger, J.S., Harpel, J.G., Giancotti, F.G. & Rifkin, D.B. Interactions between growth factors and integrins: latent forms of TGF-β are ligands for the integrin αVβ 1. Mol. Cell Biol. 9, 2627-2638 (1998).
17. Derynck, R. TGF-β-receptor-mediated signaling, TIBS 19, 548-553 (1994).
18. Saharinen, J., Taipale, J. & Keski-Oja, J. Association of the small latent TGF-β with an eight cysteine repeat of its binding protein LTBP-1. EMBO J. 15, 245-253 (1996).
19. Schultz-Cherry, S., Lawler, J. & Murphy-Ullrich, J.E. The Type 1 repeats of thrombospondin 1 activate latent TGF-β J. Biol. Chem. 269, 26783-26788 (1994).
20. Crawford, S.E. et al. Thrombospondin-1 is a major activator of TGF-β 1 in vivo. Cell 93, 1159-1170 (1998).
21. Nunes, I., Gleizes, P.-E., Metz, C.N. & Rifkin, D.B. Latent TGF-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent TGF-β J. Cell Biol. 136, 1151-1163 (1997).
22. Kojima, S., Nara, K. & Rifkin, D.B. Requirement for transglutaminase in the activation of latent TGF-β in bovine endothelial cells. J. Cell Biol. 121, 439-448 (1993).
23. Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176 (2000).
24. Peng, K.-W., Morling, F.J., Cosset, F.-L., Murphy, G. & Russell, S.J. A gene delivery system activable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8, 729-738 (1997).
25. Ye, Q.Z., Johnson, L.L., Yu, A.E. & Hupe, D. Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 34, 4702-4708 (1995).
26. Nagase, H. & Fields, G.B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 40, 399-416 (1996).
27. Saharinen, J., Hyyatiäinen, M., Taipale, J. & Keski-Oja, J. Latent TGF-β binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-β action. Cytokine Growth Factor Rev. 10, 99-117 (1999).
28. Goldman, M.H., James, D.C., Ison, A.P. & Bull, A.T. Monitoring proteolysis of recombinant human IFN-γ during batch culture of Chinese hamster ovary cells, Cytotechnology 23, 103-111 (1997).
29. Satoh, M., Hosoi, S., Miyaji, H., Itoh, S. & Sato, S. Stable production of recombinant pro-urokinase by human lymphoblastoid Namalwa KJM-1 cells: host-cell dependency of the expressed-protein stability. Cytotechnology 13, 79-88 (1993).
30. Masure, S. et al. Production and characterisation of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. Eur. J. Biochem. 244, 21-30 (1997).
31. Croxford, J.L. et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 160, 5181-5187 (1998).
32. Triantaphyllopoulos, K.A., Williams, R.O., Tailor, H. & Chernajovsky, Y. Amelioration of collagen-induced arthritis and suppression of IFN-γ, IL-12, and TNF-α production by IF-β gene therapy. Arth. Rheum. 42, 90-99 (1999).
33. Karpusas, M. et al. The crystal structure of human IFN β at 2.2-Å resolution, Biochemistry 94, 11813-11818 (1997).
34. Massova, I., Fridman, R. & Mobashery, S. Structural insights into the catalytic domains of human matrix metalloprotease-2 and human matrix metalloprotease-9; implications for substrate specificities. J. Mol. Model. 3, 17-30 (1997).
35. Wakefield, L.M. et al. Recombinant latent TGF-β1 has a longer plasma half life in rats than active TGF-β1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984 (1990).
36. Pepinsky, R. et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of IFN-β-1-a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 297, 1059-1066 (2001).
37. Han, Z., Boyle, D.L., Manning, A.M. & Firestein, G.S. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28, 197-208 (1998).
38. van Meurs, J. et al. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of Collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arth. Rheum. 42, 2074-2084 (1999).
39. Singer, I. et al. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarth. Cartil. 5, 407-418 (1997).
40. Kubota, E., Imamura, H., Kubota, T., Shibata, T. & Murakami, K. Interleukin 1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J. Oral Maxillofac. Surg. 55, 20-27 (1997).
41. Louis, E. et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin. Exp. Immunol. 120, 241-246 (2000).
42. Baugh, M. et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117, 814-822 (1999).
43. Leppert, D. et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121, 2327-2334 (1998).
44. Anthony, D.C. et al. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropath. Appl. Neurobiol. 23, 406-415 (1997).
45. Libby, P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc. Med. 3, 225-229 (1998).
46. DeClerck, Y.A. et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52, 701-708 (1992).
47. Wakefield, L. et al. Recombinant TGF-β1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-β1 complex. Growth Factors 1, 203-218 (1989).
48. Vodovotz, Y. et al. Regulation of TGF β1 by nitric oxide, Cancer Res. 59, 2142-2149 (1999).
49. Chernajovsky, Y., Adams, G., Triantaphyllopoulos, K., Ledda, M.F. & Podhajcer, O.L. Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model. Gene Ther. 4, 553-559 (1997).
50. Triantaphyllopoulos, K., Croxford, J.L., Baker, D. & Chernajovsky, Y. Cloning and expression of murine IFN β and a TNF α antagonist for retrovirus gene therapy of experimental allergic encephalomyelitis. Gene Ther. 5, 253-263 (1998).
51. Chernajovsky, Y. et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-β 1 gene fused to an SV40 early promoter. DNA 3, 297-308 (1984).
52. Ogata, Y., Itoh, Y. & Nagase, H. Steps involved in activation of the pro-matrix metalloprotease 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J. Biol. Chem. 270, 18506-18511 (1995).
53. Dreja, H., Annenkov, A. & Chernajovsky, Y. A novel truncated form of human soluble complement receptor 1 delivered by gene therapy prevents and ameliorates collagen-induced arthritis by inhibiting B and T cell responses. Arth. Rheum. 43, 1698-1709 (2000).